The objective Bayesian approach relies on the construction of prior distributions that reflect ignorance. When topologies are considered equally probable a priori, clades cannot be. Shifting justifications have been offered for the use of uniform topological priors in Bayesian inference. These include: (i) topological priors do not inappropriately influence Bayesian inference when they are uniform; (ii) although clade priors are not uniform, their undesirable influence is negated by the likelihood function, even when data sets are small; and (iii) the influence of nonuniform clade priors is an appropriate reflection of knowledge. The first two justifications have been addressed previously: the first is false, and the second was found to be questionable. The third and most recent justification is inconsistent with the first two, and with the objective Bayesian philosophy itself. Thus, there has been no coherent justification for the use of nonflat clade priors in Bayesian phylogenetics. We discuss several solutions: (i) Bayesian inference can be abandoned in favour of other methods of phylogenetic inference; (ii) the objective Bayesian philosophy can be abandoned in favour of a subjective interpretation; (iii) the topology with the greatest posterior probability, which is also the tree of greatest marginal likelihood, can be accepted as optimal, with clade support estimated using other means; or (iv) a Bayes factor, which accounts for differences in priors among competing hypotheses, can be used to assess the weight of evidence in support of clades. ©The Willi Hennig Society 2009.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1096-0031.2009.00301.x | DOI Listing |
JAMA Intern Med
January 2025
Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston.
Importance: The optimal configuration of a smoking cessation intervention in a lung cancer screening (LCS) setting has not yet been established.
Objective: To evaluate the efficacy of 3 tobacco treatment strategies of increasing integration and intensity in the LCS setting.
Design, Setting, And Participants: In this randomized clinical trial, LCS-eligible current smokers were randomized into 3 treatments: quitline (QL), QL plus (QL+), or integrated care (IC).
J Cogn
January 2025
Instituto Pluridisciplinar, Universidad Complutense de Madrid, Madrid, Spain.
The dissociation between conscious and unconscious perception is one of the most relevant issues in the study of human cognition. While there is evidence suggesting that some stimuli might be unconsciously processed up to its meaning (e.g.
View Article and Find Full Text PDFTher Adv Drug Saf
January 2025
Department of Pharmacy, Daping Hospital, Army Medical University, No. 10 Changjiang Branch Road, Yuzhong District, Chongqing 400042, China.
Background: Gilteritinib and midostaurin are FLT3 inhibitors that have made significant progress in the treatment of acute myeloid leukemia. However, their real-world safety profile in a large sample population is incomplete.
Objectives: We aimed to provide a pharmacovigilance study of the adverse events (AEs) associated with gilteritinib and midostaurin through the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.
Heliyon
January 2025
Department of Neurosurgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
Background: Growing evidence suggests that environmental pollutants exert a detrimental impact on female fertility. Among these pollutants, volatile organic compounds (VOCs), easily encountered in the environment, have garnered significant attention as prevalent airborne contaminants. Nevertheless, a definitive consensus regarding the association between VOCs and the incidence of infertility remains elusive.
View Article and Find Full Text PDFJ Alzheimers Dis
January 2025
Department of Pharmacy, Women and Children's Hospital of Ningbo University, Ningbo, China.
Background: Lecanemab, a novel monoclonal antibody targeting amyloid-β, has shown promise in treating Alzheimer's disease. Comprehensive post-marketing safety data analysis is crucial to understand its real-world risk profile.
Objective: This study aimed to evaluate the safety profile of lecanemab using data from the FDA Adverse Event Reporting System (FAERS), with a focus on nervous system disorders and amyloid-related imaging abnormalities.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!